Pricing Log in Create free account
Friday 6 November 2026 Export SEPN’s income statement to Excel — free account

Septerna, Inc.

SEPN Healthcare Biotechnology

Septerna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, up 4,174.5% from fiscal 2024.

Revenue
+22,375.6%
EPS
+48.2%
Free cash flow
−9.01%

Quarter to June 2026, against a year earlier

49.54 2.19 +4.63%
Market cap
$2.2B
P/E
0.0×
Fwd P/E
−32.6×
Dividend yield
—
F-score
5/9
Altman Z
3.41
Beneish M
32.85
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Septerna, Inc. (SEPN) Revenue

Alert me on Revenue

Septerna, Inc.'s revenue for fiscal 2025 was $46.0M, up 4,174.5% from $1.1M in fiscal 2024. Over the twelve months to 30 June 2026 it was $98.9M. Septerna, Inc. ranks 97th of 390 Biotechnology companies by revenue.

Revenue, annual

Embed this chart

Annual newest first

Period Revenue Change
FY2025 $46.0M 4,174.51%
FY2024 $1.1M 611.92%
FY2023 $151.0K —

Quarterly newest first

Period Revenue Change
Jun 2026 $26.7M 0.84%
Mar 2026 $26.5M 9.97%
Dec 2025 $24.1M 12.20%
Sep 2025 $21.5M 17,963.03%
7 more quarters

Revenue against peers

Company Revenue
BHVN Biohaven Ltd. compare $995.4M
VCEL Vericel Corporation compare $324.2M
AUPH Aurinia Pharmaceuticals Inc compare $321.7M
LKFT Lakefront Biotherapeutics - Sponsored ADR compare $282.0M
SEPN Septerna, Inc. $98.9M
PVLA Palvella Therapeutics, Inc. compare $41.6M
ZYME Zymeworks Inc. compare $37.1M
IMNM Immunome, Inc. compare $12.6M
VERA Vera Therapeutics, Inc. compare —

What Revenue is

Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.

Reported line item

The full definition of Revenue →

More on SEPN